Gene Therapy Combined with IPC Cell Induction to Treat Huntington’s Disease by Ayala, Alexandra et al.
Eukaryon
Volume 5
Celebrating Darwin's 100th Anniversary Article 22
3-21-2009
Gene Therapy Combined with IPC Cell Induction







Follow this and additional works at: https://publications.lakeforest.edu/eukaryon
Disclaimer:
Eukaryon is published by students at Lake Forest College, who are solely responsible for its content.
The views expressed in Eukaryon do not necessarily reflect those of the College. Articles published
within Eukaryon should not be cited in bibliographies. Material contained herein should be treated
as personal communication and should be cited as such only with the consent of the author.
This Grant Proposal is brought to you for free and open access by the Student Publications at Lake Forest College Publications. It has been accepted for
inclusion in Eukaryon by an authorized editor of Lake Forest College Publications. For more information, please contact levinson@lakeforest.edu.
Eukaryon, Vol. 5, March 2009, Lake Forest College                                               Grant Proposal 
 
32 
Gene Therapy Combined with IPC Cell Induction to Treat Huntington’s 
Disease 
 
Alexandra Ayala, Daryn Cass, and Michael Fiske* 
Department of Biology 
Lake Forest College 




Huntington’s disease (HD) results from expansion of 
CAG repeats in the huntingtin gene in chromosome 4, 
resulting in misfolded and aggregated huntingtin protein 
inside medium spiny neurons.  In HD, these neurons 
ultimately die, resulting in the classical symptoms of the 
disease.  Current treatments for HD are ineffective, as 
none attempt to treat the source of the disease. A new 
method that attempts to correct the expanded huntingtin 
gene is needed for effective, long term treatment of the 
disease. Recent advances in the field of induced 
pluripotent stem cells and gene therapy have shown 
that induction of pluripotency combined with 
homologous recombination can correct genetic disease 
in mice.  We propose the hypothesis that fibroblasts 
from HD model mice and human HD patients can be 
transformed into IPS cells.  After IPS cell formation, the 
huntingtin gene will be repaired using homologous 
recombination, and the cells will be directly 
differentiated into medium spiny neurons.  
Transplantation of the neurons into HD mice models 
representing healthy, mild, and severe forms of the 
disease will follow, and improvements in HD related 
symptoms will be evaluated.  Perfection of our methods 





Neurodegenerative disease is a broad term used to describe 
a state of selective neuronal death.  The death of neurons 
results in the symptoms of the disease, and these symptoms 
are usually characteristic of the specific disease the patient 
is suffering from (1).  For example, in Parkinson’s disease 
(PD), dopaminergic neurons of the substantia nigra are lost, 
resulting in movement based symptoms (2).  In Alzheimer’s 
disease (AD), the memory deficits seen in patients are the 
consequence of neuronal death in the hippocampus (3).  
The reason for the neuronal degeneration, however, is 
complex and varied.  While many of the currently known 
neurodegenerative diseases are of sporadic origin, a number 
of these neurodegenerative diseases can be traced to 
genetic mutations, such as the familial mutations known to 
cause PD (4).  Current treatments for these diseases are 
insufficient, as they do not fix the source of the disease and 
only seek to ease symptoms.  Since there is no way to slow 
or stop disease progression, treatment typically consists of 
physical rehabilitation to improve movement symptoms and 
drug use to treat emotional symptoms (5). 
One such neurodegenerative disease of specific 
interest is Huntington’s disease (HD).  HD is a late onset 
autosomal-dominant neurodegenerative disorder 
characterized by death of neurons in the caudate nucleus (5, 
6).   Symptoms include psychiatric disturbances, motor 
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impairment, and cognitive decline and typically present 
themselves in midlife.   The disease is a trinucleotide repeat 
disease caused by a CAG repeat expansion in the IT15 
gene on the short arm of chromosome 4, resulting in a long 
stretch of polyglutamine in the encoded huntingtin (htt) 
protein (7).  Adults with between six and thirty-five CAG 
repeats in the IT15 gene have been found to be 
asymptomatic.  When more than thirty-six CAG repeats are 
present, HD will most likely develop.  The length of the CAG 
expansion is inversely correlated with age of disease onset, 
and juvenile cases of HD are characterized by expansions of 
more than sixty repeats (5).  The polyglutamine expansions 
in HD lead to characteristic patterns of neurodegeneration, 
including the death of -aminobutyric (GABA) acid-releasing 
spiny-projection neurons of the striatum as well as loss of 
neurons in the hippocampus and cortex (6). Protein 
aggregation has also been shown to play a role in HD as in 
some other neurodegenerative diseases, such as PD and 
AD. There is characteristic formation of intranuclear 
inclusions (NIIs) of the huntingtin protein in the striatum 
which stain positively for ubiquitin, indicating that protein 
degradation occurs.  The timing of appearance of NIIs 
parallels the cognitive and motor decline in mice. This 
indicates that protein aggregation plays an important role in 
the progression of Huntington’s disease. However, exact 
mechanisms by which progression takes place remain to be 
identified (8).  
No effective treatment currently exists to prevent 
or slow the loss of these neurons, although previous 
research on tissue transplantation from unaffected patients 
into HD patients has shown promise (9).  Additionally, the 
use of histone deacetylase inhibitors is being investigated as 
a potential treatment method (4).  Other small molecules that 
prevent aggregation of huntingtin protein are currently being 
studied as potential HD treatments as well (4).  However, 
most of these treatments are still being conducted in model 
organisms, and the move to clinical trials is time consuming 
and expensive.  Other alternatives should be pursued. 
One potential treatment involves the use of stem 
cells to replace dying neurons.  Embryonic stem cells (ES) 
are a type of pluripotent cells located in the inner mass of a 
developing blastocyst.  These cells are capable of dividing 
repeatedly while still retaining the ability to differentiate into 
tissue from any of the three germ layers (10).  This capacity 
for self renewal and tissue specific differentiation makes ES 
cells promising tools in regenerative medicine.  ES cells 
derived from developing mice embryos successfully 
integrated into the striatum and reduced symptoms in a drug 
induced PD mice model (11).  Application of ES cell therapy 
to treat human disease is limited by rejection of donor cells 
and the current techniques used to harvest the cells.  
Modern methods require the destruction of a developing 
embryo to obtain human ES cells, raising a moral debate in 
the political arena (12).  Consequently, the pressure to 
develop a new approach to obtain pluripotent cells led to the 
discovery of induced pluripotent stem cells (IPS). 
 IPS cells are derived from somatic cells that have 
been reprogrammed to an ES cell-like state using a cocktail 
of four transcription factors delivered by retroviruses.   The 
transcription factors c-Myc, Oct3/4, Sox2, and Klf4 are 
sufficient to reprogram a human fibroblast into an IPS cell 
that has the ability to differentiate into all three germ layers 
(13).  The source of these pluripotent cells bypasses any 
ethical opposition, and thus is a promising technique to use 
in disease treatment.  The patient-specific origin of these 
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cells also circumvents immune rejection.   IPS cells have 
been used successfully to treat rats in a PD model, and IPS 
cells from human patients with a number of genetic diseases 
have also been generated.  More specifically, fibroblasts 
cells from two Amyotrophic Lateral Sclerosis (ALS) patients 
were transformed into IPS cells and directly differentiated 
into the motor neurons affected by the disease (10, 14).  The 
genetic mutation that causes ALS was present in the 
genome of these disease specific IPS cells (dsIPS).  The 
differentiation techniques used to generate the motor 
neurons involved manipulation of the sonic hedgehog (SHH) 
pathway combined with retinoic acid treatment (14).  It has 
been suggested that the timing and concentration of retinoic 
acid and SHH protein addition influences the type of 
resulting neuronal differentiation (15, 16). 
 In addition to IPS cells, gene therapy has emerged 
as a powerful tool to correct genetic mutations for use in 
regenerative medicine.  Previously, genetic defects in mice 
ES cells have been successfully treated using homologous 
recombination gene therapy (17).  Recently, generation of 
IPS cells from a rat sickle cell anemia model and subsequent 
homologous recombination gene therapy to correct the 
sickle cell mutation improved symptoms in the rats (17, 18, 
19).  This proof of principle experiment furthers the 
possibility of using IPS cell induction combined with gene 
therapy to treat the disease.  However, generation of the IPS 
cells using potentially tumorigenic oncogenes delivered by 
retrovirus is undesirable (20).  Recent advances have 
utilized a plasmid based delivery system that circumvents 
the integration of genes into the host genome (21).  The 
ability to combine this plasmid based delivery with gene 
therapy to correct disease genetics and how plasmid 
delivery differs from retroviral delivery, however, is currently 
not known.  Additionally, the feasibility of differentiating these 
corrected IPS cells into the desired tissue and using them for 
disease specific treatment has not been assessed.  
Therefore, we hypothesize that HD fibroblasts can be 
genetically repaired and differentiated into neurons for 
treatment in HD.  Thus, we propose to induce the formation 
of IPS cells using fibroblasts from a mouse HD model and 
human HD patients followed by successive homologous 
recombination gene therapy to correct the HD gene in the 
newly formed IPS cell.  Directed differentiation of the IPS 
cells into GABAergic releasing spiny projection neurons and 
insertion of corrected mice and human neurons into the 




The expansion of biological knowledge in the past century 
has been immense.  Discoveries such as penicillin and 
vaccines have lead to a dramatic reduction in deaths caused 
by infectious disease.  However, the genetic basis for 
inherited diseases and our inability to treat them effectively 
reflects a serious deficit in our treatment arsenal.  Perfecting 
the methods we intend to utilize in our studies and 
successfully treating HD symptoms using IPS cells opens 
the door to application in a plethora of other genetic 
diseases, and in the process, benefit all of mankind.  
Development of an effective HD treatment could potentially 
save the lives of the 30,000 people currently suffering from 
the disease in the United States alone (4). 
Our proposal has significant relevance to the 
scientific field as it will give insight into the genetic 
mechanisms of HD.  Although the disease is well studied, 
the actual cause of the CAG repeats is not well understood.  
While investigating methods to correct the HD gene, 
discoveries that further our knowledge of the disease will 
inevitably be made. Our study will also contribute heavily to 
the molecular knowledge of IPS cell therapy and 
differentiation techniques.  In addition, successful use of 
gene therapy will help the technique become more widely 




Our ultimate goal is to develop an effective treatment for 
Huntington’s disease. Mouse fibroblasts from an HD mouse 
model, as well as human fibroblasts will be used to create 
IPS cells.  Homologous recombinant gene therapy will be 
applied to correct the HD CAG repeats in the IPS cell 
genome.  Based on previously established methods, the 
corrected IPS cells will be differentiated into medium spiny 
neurons and then implanted into the brains of HD mice.  We 
hypothesize that implanting these neurons into the diseased 
mice will alleviate their symptoms. 
 
1. Treating diseased Huntington mice models with corrected 
IPS cells from mice 
Fibroblasts from adult HD mouse models will be 
reprogrammed into IPS cells using a retrovirus or a plasmid 
carrier. Homologous recombination will replace the diseased 
huntingtin gene in IPS cells with a healthy gene. 
Furthermore, we will directly differentiate recombinant IPS 
cells into the specific neurons affected in HD.  These 
neurons will then be injected into the striatum of mouse 
brains, the location of neurodegeneration in HD. Finally, we 
will use immunostaining to assess pluripotency, PCR to 
evaluate successful gene replacement after homologous 
recombination, and GFP expression to confirm successful 
differentiation and implantation of neurons.  
 
2.  Treating diseased Huntington mice models with corrected 
IPS cells from humans 
Fibroblasts from adult HD humans will be reprogrammed into 
IPS cells by use of a retrovirus or a plasmid carrier. 
Homologous recombination will replace the diseased 
huntingtin gene in IPS cells with a healthy gene. 
Furthermore, we will directly differentiate recombinant IPS 
cells into the specific neurons affected in HD. In order to 
avoid rejection, neurons will be injected into the striatum of 
immunosuppressant mouse brains. Finally, we will use 
immunostaining to assess pluripotency, PCR to evaluate 
successful gene replacement after homologous 
recombination, and GFP expression to confirm successful 
differentiation and implantation of neurons.  
 
3.  Treating diseased Huntington mice models with healthy 
IPS cells from humans 
Healthy fibroblasts from adult humans will be reprogrammed 
into IPS cells by use of a retrovirus or a plasmid carrier. We 
will then directly differentiate IPS cells into the specific 
neurons affected in HD. In order to avoid rejection, neurons 
will be injected into the striatum of immunosuppressant 
mouse brains. Finally, we will use immunostaining to assess 
pluripotency and GFP expression to confirm successful 
differentiation and implantation of neurons. 
 
Research Method and Design 
 
1.  Treating diseased Huntington mice models with corrected 
IPS cells from mice 
1. Rationale: To evaluate the therapeutic potential of 
the proposed method, Huntington mice models will 
be treated with their own neurons containing a 
huntingtin gene repaired using homologous 
recombination.  Retroviral reprogramming of 
fibroblasts is a proven method for reestablishing 
pluripotency in adult mice fibroblast cells (13).  
Due to possible tumorigenesis from retroviral 
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vector integration, insertion of the reprogramming 
factors will also be done using a plasmid (21).  
Homologous recombination can correct gene 
mutations in mice.  Thus, we will use this method 
to replace the HD gene with a normal, low repeat 
gene.   
2. Design and Method:  Two sets of three groups of 
HD model mice will be used.  The three groups will 
consist of mice with a healthy/control number of 
CAG repeats, a low number of CAG repeats (40-
50, moderate disease), and a high number of CAG 
repeats (70, severe disease).  One set of mice will 
be treated with their own genetically corrected and 
differentiated GABAergic neurons and the other 
will be treated with uncorrected and differentiated 
neurons.  Furthermore, each group will be divided 
into two subcategories for a total of six mouse 
groups per set.  The purpose of the division is to 
compare reprogramming technologies; one 
subcategory will be transduced with the retrovirus 
and the other with the plasmid carrier.  The 
healthy mouse groups will serve as a control for 
the moderately diseased, low repeat models and 
the severely symptomatic, high repeat models.   
a)  Development of transgenic mice: Mice will be 
generated that are transgenic for the 5’ end of the 
human HD gene carrying less than 40, 40 to 50, 
and more than 70 CAG repeat expansions as 
previously described (7). In this experiment it was 
shown that mice with a particular amount of CAG 
repeats will acquire an HD phenotype and show 
late onset neurodegeneration of the dorsal 
striatum. 
b)  Creating IPS cells:  Fibroblasts will be extracted 
from control, high, and low repeat mice and 
disease genotype will be verified using DNA 
sequencing. Transgenes encoding KLF4, SOX2, 
OCT4, and c-Myc will be introduced into mice 
fibroblasts from all three groups by means of 
vesicular stomatitis glycoprotein (VSVg) 
pseudotyped Maloney retrovirus (9, 15). At this 
point, fibroblast will be tagged with green 
fluorescent protein (GFP) in order to provide a 
clear outline of cells once they have been 
implanted into a mouse model. This will allow us to 
determine their location and shape.  Fibroblasts 
will be transduced twice over 72 hours, cultured 
for 4 days in standard fibroblast medium, and then 
passaged onto a feeder layer of mouse embryonic 
fibroblasts in an ES cell supportive medium.  After 
two weeks, we expect to see a small number of 
colonies with morphology similar to ES cells.  
Several lines will be selected and clonally 
expanded.  Mice fibroblasts from each group will 
also be reprogrammed by means of a plasmid-
based delivery system as previously described 
(20). DNA fingerprinting analysis will be performed 
to verify that each of the IPS cell lines created 
matches that of the mouse from which they were 
derived, has the mutation in the huntingtin protein, 
and the correct number of CAG repeats (15).  
Furthermore, polymerase chain reaction (PCR) 
analysis of genomic DNA will be performed in 
order to verify that they all carry integrated copies 
of the four retroviral transgenes for which they 
were transduced (15, 22).  Also, to verify that the 
reprogramming of the fibroblasts is successful and 
that the putative IPS cells are pluripotent, their 
similarity to embryonic stem cells will be 
determined.  To accomplish this, the expression of 
several ES cell associated antigens (SSEA-3, 
SSEA-4, TRAI-60, TRAI-81, and NANOG) will be 
verified (15).  We will also confirm that the IPS 
lines created are not immunoreactive for the 
fibroblast associated antigen TE-7.  Quantitative 
reverse transcription PCR will be used to measure 
transcript levels of several genes expressed in 
pluripotent cells.  We will look at the levels of 
REX1/ZFP42, FOXD3, TERT, NANOG, and 
CRIPTO/TDGF1 to confirm that these are 
transcribed at levels comparable to ES cells in 
each of our created lines (22).  Pluripotent cells 
are, by definition, able to readily form embryoid 
bodies composed of cells representative of the 
three embryonic germ layers.  Immunostaining will 
be performed to verify this.  Staining for desmin, -
fetoprotein, and -tubulin IIIb will be performed to 
assess pluripotent ability (15, 22).   
c)  Gene correction: Custom plasmids with a healthy 
IT-15 gene encoding the huntingtin protein will be 
inserted into one set of diseased IPS cells by 
electroporation; the second set will be left 
untouched. Diseased genes in the presence of the 
plasmid will be corrected with the healthy gene via 
homologous recombination. Corrected cells will be 
transferred to hygomycin and gancyclovir 
containing media for 2 weeks.  Custom primers 
and PCR will be used to identify homologous 
recombinants in IPS cells derived from diseased 
mice (9).   
d) Motor Neuron differentiation:  The hallmark of HD 
is depletion of GABA releasing spiny projection 
neurons in the striatum.  Differentiation of such 
neurons relies on the sonic hedgehog (SHH) 
pathway and retinoic acid treatment. Corrected 
and uncorrected IPS cells will be differentiated into 
GABAergic neurons by manipulation of the SHH 
pathway and exposure to retinoic acid as 
previously described (15, 23).  100,000 to 300,000 
GABAergic spiny-projection neurons from the IPS 
lines expressing GFP will be transplanted into the 
lateral brain ventricles of mice (9).    
e) Behavioral tests: In order to assess recovery of 
Huntington’s disease, two behavioral models will 
be used to compare mice treated with the 
corrected and uncorrected cells. The first test, the 
RotaRod test involves the placement of the mouse 
on a spinning rod which moves at a speed slightly 
faster than walking speed (24, 25).  Performance 
will be scored by the amount of time the mouse is 
able to stay on the moving rod.  This test is used 
in order to evaluate an animal’s sense of balance 
and coordination, two abilities that are affected in 
Huntington’s disease. The second test used will be 
the footprint test. HD patients frequently 
experience abnormalities in gait and impairments 
in sensorimotor gaiting. This test is frequently 
used to determine the extent of these impairments 
in a mouse model of HD. We will perform the 
footprint test in order to compare the gait of HD 
mice with non HD mice. The front and hind limbs 
of animals will be painted two different colors. 
Mice will walk down a 50 cm long and 10 cm wide 
runway. Stride length, hind-base width, front-base 
width, and front footprint/hind footprint overlap. 
(26). Diseased mice are expected to spend less 
time on the RotaRod and are expected to show 
more irregularities in gait.  
f) Neuropathology of disease: After performance in 
the behavioral tests, all mice will be sacrificed.  
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Brains will be removed and cut into coronal 
sections.  First, we will seek evidence of 
integration of transplanted IPS cells.  Before the 
development of IPS cell colonies, reprogrammed 
fibroblasts will have been tagged with GFP. 
Immunofluorescent staining will allow us to verify 
that grafted cells moved to the striatum, and will 
provide a clear outline of incorporated cells, with 
definition of their shapes and neuronal processes 
(27). Electrophysiological recordings will also be 
performed to examine the functionality of grafted 
cells.  Synaptic inputs and outputs will be 
determined for several cells from each animal and 
compared to normal ranges (27).   
To determine the recovery of HD mice, 
several neuropathological stains will be performed 
on the tissue.  Density of GABAergic neurons in 
the striatum and DARPP-32 expressing striatal 
projection neurons will be determined. We will also 
assess cell death in the striatum and perform a 
TUNEL stain, a marker for apoptotic cells, to 
determine levels of cell death (28). NIIs are shown 
to be present in the striatum of transgenic mice. 
Ab 1 is an antiserum against huntingtin and 
produces intense labeling for huntingtin localized 
to neuronal intranuclear inclusions. Therefore, it 
can be used to indentify NIIs (29). Levels of NIIs 
will be compared in mice from different groups. 
Size of the striatum as well as other central 
nervous system structures has previously been 
shown to be smaller in transgenic animals than in 
wild-type mice (7). We will compare the size of 
coronal sections of the normal, low, and high CAG 
repeat mice to one another to confirm these 
changes in size.   Ultimately, performance of the 
behavior test will be correlated with data from 
neuropathology in order to determine the effects of 
IPS cell implantation.  We expect to see an 
increase in GABAergic spiny-projection neurons in 
the striatum as well as other regions, possibly 
correlating with a decrease in symptoms (30, 31). 
Prediction:  We predict that the mildly diseased mice treated 
with fixed neurons will show the biggest improvement in 
symptoms.  Severely diseased mice will also show 
improvements, albeit not to such a large extent as the mildly 
diseased.  The mice models implanted with unfixed neurons 
will not show any improvement.   
 
2.  Treating diseased Huntington mice models with corrected 
IPS cells from humans 
1) Rationale: Huntington mice models will be treated 
with human HD neurons containing a huntingtin 
gene repaired using homologous recombination. 
To avoid rejection, immunosuppressant mice will 
be used.  Retroviral reprogramming is a proven 
method for establishing pluripotent IPS cells from 
adult human fibroblast cells (13, 20, 21).  Due to 
possible tumorigenesis from retroviral vector 
reactivation, the factors will also be inserted using 
a plasmid carrier (21).  
2) Design and Method: Two sets of three groups of 
immunosuppressant mice will be used to model a 
non-diseased HD patient, a low CAG repeat 
patient and a high CAG repeat patient. One set of 
mice will be treated with genetically corrected and 
differentiated human GABAergic neurons and the 
other will be treated with uncorrected and 
differentiated neurons. The remainder of the 
design will correspond to that of aim 1.  
a) Development of transgenic mice: Mice will be 
developed that are transgenic for the 5’ end of the 
human HD gene with less than 40, 40-50, or more 
than 70 CAG repeats as described in aim 1.  
b) Creating IPS cells:  Activation of c-Myc, KLF4, 
OCT-4 and Sox2 transcription factors in adult 
human fibroblasts with retrovirus or plasmid 
carriers will follow the protocol previously 
described (15, 20).  IPS cell pluripotency will be 
verified as stated in aim 1.   
c) Gene correction: Control, low and high repeat HD 
genes in human IPS cells will be replaced with 
healthy HD genes.  Plasmids containing the 
healthy IT-15 gene will be inserted into one set of 
diseased IPS cells for correction and the second 
set will be left uncorrected. Custom primers and 
PCR will be used to identify homologous 
recombinants in IPS cells derived from diseased 
humans (9).   
d) Motor Neuron differentiation: Corrected and 
uncorrected IPS will be differentiated into 
GABAergic neurons and inserted into the mouse 
brains as explained in aim 1.  
e) Behavioral tests: Two behavioral tests called the 
RotaRod and the footprint test will be used to 
assess progression of Huntington’s disease in the 
mice.  The tests will be performed as explained in 
aim 1. 
f) Neuropathology of disease: After performance of 
the behavioral tests, mice will be sacrificed.  
Brains will be removed and cut into coronal 
sections.  Immunofluorescent labeling for GFP and 
electrophysiological recordings will be performed 
as explained in aim 1 to verify successful 
integration and function of engrafted cells.  To 
assess recovery from disease, density of 
GABAergic and DARPP-32-ir neurons will be 
quantified. Size of striatum and levels of NIIs and 
cell death will be determined as explained in aim 
1. 
Prediction:  We predict that the mildly diseased mice treated 
with fixed human neurons will show the biggest improvement 
in symptoms.  Severely diseased mice will also show 
improvements, albeit not to such a large extent as the mildly 
diseased.  The mice models implanted with unfixed human 
neurons will not show any improvement. 
 
3.  Treating diseased Huntington mice models with healthy 
IPS cells from humans  
1) Rationale: Aims one and two rely on homologous 
recombination and directed differentiation to 
create neurons capable of treating HD mouse 
models.  To evaluate whether our method works 
with non-diseased cells, we will inject an HD 
mouse model with neurons transformed from 
humans without HD.  Comparing both procedures 
will give an indication of how reliable homologous 
recombination is for correcting IPS cells and 
treating HD.   
2) Design and Method: Two sets of three groups of 
immunosuppressant mice will be used to model a 
non-diseased HD patient, a low CAG repeat 
patient and a high CAG repeat patient. Mice will 
be treated with differentiated human GABAergic 
neurons derived from healthy human fibroblasts. 
The remainder of the design will correspond to 
that of aim 1.  
a) Creating IPS cells: Activation of c-Myc, KLF4, 
OCT-4 and Sox2 transcription factors in adult 
human fibroblasts with retrovirus or plasmid 
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carriers will follow the protocol previously 
described (15, 20).  IPS cell pluripotency will be 
verified as stated in aim 1.   
b) Motor Neuron differentiation: Corrected and 
uncorrected IPS will be differentiated into 
GABAergic neurons and inserted into the mouse 
brains as explained in aim 1.  
c) Behavioral tests: Two behavioral tests called the 
RotaRod and the footprint test will be used to 
assess progression of Huntington’s disease in the 
mice.  The tests will be performed as explained in 
aim 1. 
d) Neuropathology of disease: After performance in 
the behavioral tests, mice will be sacrificed.  
Brains will be removed and cut into coronal 
sections.  Immunofluorescent labeling for GFP and 
electrophysiological recordings will be performed 
as explained in aim 1 to verify successful 
integration and function of engrafted cells.  To 
assess recovery from disease density of 
GABAergic and DARPP-32-ir neurons will be 
quantified. Size of striatum and levels of NIIs and 
cell death will be determined as explained in aim 
1. 
Prediction:  The mildly diseased mice models will show the 
largest improvement in HD related symptoms upon 
transplantation of differentiated GABAergic neurons.  The 
severely diseased HD models will also show improvement 
but to a lesser extent. 
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